Oral scopolamine augmentation for major depression

Expert Review of Neurotherapeutics

Volumn 13, Issue 1, 2013, Pages 19-21

  Han, Changsu ^a   Pae, Chi Un ^b,c  

^a Korea University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antidepressant; augmentation; depression; scopolamine

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; CREATINE; PLACEBO; QUETIAPINE; SCOPOLAMINE; SCOPOLAMINE BROMIDE; SEROTONIN UPTAKE INHIBITOR;

BLURRED VISION; CLINICAL PRACTICE; COGNITIVE DEFECT; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REMISSION; REVIEW; XEROSTOMIA;

EID: 84871582833     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.150     Document Type: Review

References (13)

1. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 25(2), 109-127 (2011).
2. Lyoo IK, Yoon S, Kim TS et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am. J. Psychiatry 169(9), 937-945 (2012).
3. Janowsky DS, Overstreet DH. Cholinergic dysfunction in depression. Pharmacol. Toxicol. 66(Suppl. 3), 100-111 (1990).
4. Khajavi D, Farokhnia M, Modabbernia A et al. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 73(11), 1428-1433 (2012).
5. Chew ML, Mulsant BH, Pollock BG et al. Anticholinergic activity of 107 medications commonly used by older adults. J. Am. Geriatr. Soc. 56(7), 1333-1341 (2008).
6. Trumic E, Pranjic N, Begic L, Becic F, Asceric M. Idiosyncratic adverse reactions of most frequent drug combinations longterm use among hospitalized patients with polypharmacy. Med. Arh. 66(4), 243-248 (2012).
7. Kumar S, Kulkarni SK. Influence of antidepressant drugs on learning and memory paradigms in mice. Indian J. Exp. Biol. 34(5), 431-435 (1996).
8. Pae CU, Sohi MS, Seo HJ et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 34(7), 1165-1173 (2010).
9. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am. J. Psychiatry 152(10), 1500-1503 (1995).
10. Rush AJ, Warden D, Wisniewski SR et al. STAR*D: revising conventional wisdom. CNS Drugs 23(8), 627-647 (2009).
11. Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol. Sci. 30(3), 148-155 (2009).
12. Drapier D, Péron J, Leray E et al. Emotion recognition impairment and apathy after subthalamic nucleus stimulation in Parkinson's disease have separate neural substrates. Neuropsychologia 46(11), 2796-2801 (2008).
13. Tayebati SK, Amenta F, El-Assouad D, Zaccheo D. Muscarinic cholinergic receptor subtypes in the hippocampus of aged rats. Mech. Ageing Dev. 123(5), 521-528 (2002).